Hepion Pharmaceuticals, Inc. (HEPA) Business Model Canvas

Hepion Pharmaceuticals, Inc. (HEPA): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Hepion Pharmaceuticals, Inc. (HEPA) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Hepion Pharmaceuticals, Inc. (HEPA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of pharmaceutical innovation, Hepion Pharmaceuticals emerges as a beacon of hope for patients battling complex liver diseases. With a laser-focused approach on developing groundbreaking therapeutics, particularly targeting non-alcoholic steatohepatitis (NASH), this dynamic biotech company is pioneering a transformative journey through its meticulously crafted Business Model Canvas. By leveraging cutting-edge CRF inhibitor technology and strategic collaborations, Hepion is not just developing drugs, but reimagining the future of liver disease treatment—promising potential breakthroughs that could revolutionize patient care and medical interventions.


Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Key Partnerships

Academic Research Institutions Collaboration

Institution Collaboration Focus Research Area
University of California, San Diego NASH Research Preclinical Drug Development
Mayo Clinic Liver Disease Studies Clinical Trial Support

Pharmaceutical Strategic Partners

Current Clinical Trial Collaboration Partners:

  • Medpace, Inc. - Contract Research Organization
  • ICON plc - Global Clinical Research Services

Contract Research Organizations (CROs)

CRO Name Contract Value Study Phase
Medpace $3.2 million Phase 2 NASH Trials
ICON plc $2.7 million Preclinical Studies

Licensing Partners

Potential Commercialization Partners:

  • Gilead Sciences - Potential liver disease treatment licensing
  • AbbVie Inc. - NASH therapeutic partnership discussions

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Key Activities

Research and Development of Novel Therapeutics for Liver Diseases

As of Q4 2023, Hepion Pharmaceuticals has invested $12.3 million in research and development efforts focused on liver disease therapeutics.

R&D Focus Area Investment Amount Research Stage
CRF Inhibitor Pipeline $7.5 million Phase 2 Clinical Trials
NASH Treatment Development $4.8 million Preclinical Research

Conducting Clinical Trials for CRF Inhibitor Pipeline

Current clinical trial portfolio includes:

  • 2 active Phase 2 clinical trials
  • Total clinical trial budget of $9.2 million for 2024
  • Patient enrollment target of 180 participants

Developing Treatments for Non-Alcoholic Steatohepatitis (NASH)

NASH Treatment Development Metrics 2024 Values
Research Personnel 12 specialized researchers
Annual Research Budget $5.6 million
Potential Drug Candidates 3 in preclinical stage

Regulatory Compliance and Drug Approval Processes

Compliance expenditure for 2024: $2.1 million

  • FDA interaction meetings: 4 scheduled
  • Regulatory documentation preparation team: 6 professionals

Intellectual Property Management and Protection

IP Category Number of Assets Annual Protection Cost
Active Patents 7 $1.3 million
Patent Applications 3 $450,000

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Key Resources

Proprietary CRF Inhibitor Technology Platform

CRF (Cyclin-Dependent Kinase) Inhibitor Technology represents a critical resource for Hepion Pharmaceuticals:

Technology Attribute Specific Details
Technology Focus Liver disease therapeutic interventions
Patent Status Multiple issued patents protecting core technology
Development Stage Advanced preclinical and clinical development phases

Scientific and Research Expertise in Liver Disease Therapeutics

Hepion's research capabilities include:

  • Specialized research team with extensive hepatology background
  • Collaborative networks with academic research institutions
  • Expertise in developing targeted liver disease treatments

Patent Portfolio for Drug Candidates

Patent Category Number of Patents Protection Scope
Core CRF Inhibitor Technology 7 issued patents Global pharmaceutical markets
Specific Drug Candidate Compositions 3 pending patent applications Novel molecular structures

Research and Development Facilities

Hepion's R&D infrastructure includes:

  • Dedicated laboratory spaces in San Diego, California
  • Advanced molecular biology research equipment
  • Computational modeling and drug design capabilities

Specialized Medical and Scientific Talent Pool

Professional Category Number of Professionals Expertise Areas
PhD-Level Researchers 12 full-time researchers Hepatology, Pharmacology, Molecular Biology
Clinical Development Specialists 8 clinical research professionals Clinical trial design and management

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Value Propositions

Innovative Therapeutic Approach for Liver Disease Treatment

Hepion Pharmaceuticals focuses on developing CRV431, a cyclophilin inhibitor targeting non-alcoholic steatohepatitis (NASH). Clinical trial data as of Q4 2023 indicates:

Clinical Parameter Measurement
CRV431 Treatment Potential Reduction of liver fibrosis progression
Clinical Stage Phase 2 clinical trials
Target Patient Population NASH patients with liver fibrosis

Potential Breakthrough in NASH Management

Key therapeutic targets include:

  • Cyclophilin inhibition mechanism
  • Potential reduction of liver inflammation
  • Mitigation of fibrosis progression

Advanced Small Molecule Drug Development

Research and development investment metrics:

Financial Metric Amount
R&D Expenditure (2023) $12.4 million
Patent Applications 7 active pharmaceutical compositions

Targeted Treatment Options for Complex Liver Conditions

Therapeutic focus areas:

  • Non-alcoholic steatohepatitis (NASH)
  • Liver fibrosis
  • Hepatic inflammation

Potential Reduction of Liver Disease Progression and Complications

Clinical development milestones:

Clinical Development Stage Status
Phase 2 Clinical Trials Ongoing patient enrollment
Anticipated Clinical Endpoints Liver fibrosis regression

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Customer Relationships

Direct Engagement with Medical Research Community

As of Q4 2023, Hepion Pharmaceuticals maintained direct engagement through 37 active research collaborations with academic and medical institutions.

Engagement Type Number of Collaborations Research Focus
Academic Partnerships 22 NASH and Liver Disease Research
Clinical Research Networks 15 CRN-001 Clinical Trials

Scientific Conference and Symposium Presentations

In 2023, Hepion Pharmaceuticals presented at 12 international medical conferences, with 8 focused on hepatology and liver disease research.

  • American Association for the Study of Liver Diseases (AASLD) Conference
  • International Liver Congress
  • Experimental Biology Conference

Transparent Communication of Clinical Trial Progress

Hepion reported 4 active clinical trials as of December 2023, with quarterly progress updates shared through investor communications and scientific publications.

Clinical Trial Patient Enrollment Current Status
CRN-001 NASH Trial 180 patients Phase 2b Active

Collaboration with Hepatology Specialists

The company maintained professional relationships with 64 hepatology specialists across North America and Europe in 2023.

Patient Advocacy Group Interactions

Hepion engaged with 7 patient advocacy organizations focused on liver disease and metabolic disorders during 2023.

  • American Liver Foundation
  • NASH Education Program
  • Fatty Liver Foundation

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Channels

Scientific Publications and Peer-Reviewed Journals

Hepion Pharmaceuticals has published research in the following journals in 2023:

Journal Name Number of Publications Focus Area
Hepatology 3 NASH and Liver Disease
Journal of Hepatology 2 Viral Hepatitis Research

Medical Conferences and Industry Events

Conference participation details for 2023:

Conference Date Presentation Type
AASLD Liver Meeting November 2023 Oral Presentation
International Liver Congress April 2023 Poster Presentation

Direct Communication with Pharmaceutical Partners

Partner communication channels:

  • Direct email communications
  • Quarterly partnership review meetings
  • Confidential data sharing platforms

Investor Relations Platforms

Investor communication metrics for 2023:

Platform Number of Investor Interactions Quarterly Earnings Calls
Investor Webinars 4 4
SEC Filings 12 N/A

Regulatory Agency Submissions

Regulatory submission details:

Agency Number of Submissions Submission Type
FDA 2 Clinical Trial Protocols
EMA 1 Investigational New Drug Application

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Customer Segments

Hepatology Medical Specialists

As of 2024, approximately 3,500 hepatology specialists in the United States. Target market size estimated at $12.4 million potential annual engagement.

Specialist Category Total Number Potential Market Penetration
Board Certified Hepatologists 3,500 65%
Academic Medical Center Specialists 1,200 45%

Research Institutions

Targeted research institutions focused on liver disease research: 287 globally.

  • North American Research Centers: 124
  • European Research Institutions: 93
  • Asian Research Facilities: 70

Pharmaceutical Companies

Target market includes 42 pharmaceutical companies with liver disease research programs.

Company Size Number of Companies Potential Collaboration Interest
Large Pharmaceutical Companies 12 High
Mid-Size Pharmaceutical Companies 18 Medium
Small Specialized Companies 12 Low

Patients with Liver Diseases

Total addressable patient population: 4.5 million in the United States with chronic liver diseases.

  • Non-Alcoholic Fatty Liver Disease (NAFLD): 2.3 million
  • Hepatitis C: 900,000
  • Cirrhosis: 630,000
  • Other Liver Conditions: 670,000

Healthcare Providers Focused on Metabolic Disorders

Total healthcare providers specializing in metabolic disorders: 8,700 nationwide.

Provider Type Total Providers Potential Engagement Rate
Endocrinologists 5,200 55%
Metabolic Disease Specialists 2,100 75%
Advanced Practice Providers 1,400 40%

Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year ended December 31, 2022, Hepion Pharmaceuticals reported R&D expenses of $14.2 million.

Year R&D Expenses
2022 $14.2 million
2021 $16.9 million

Clinical Trial Investments

Clinical trial costs for CRV431 (liver disease treatment) were approximately $7.5 million in 2022.

  • Phase 2 clinical trials for NASH indication
  • Ongoing clinical development programs

Intellectual Property Protection Costs

Patent and trademark protection expenses were approximately $450,000 in 2022.

Regulatory Compliance Expenditures

Regulatory compliance and submission costs totaled approximately $1.2 million in 2022.

Personnel and Talent Acquisition Costs

Cost Category Amount
Total Personnel Expenses $8.3 million
Executive Compensation $2.1 million
Stock-Based Compensation $1.5 million

Total Operational Costs for 2022: Approximately $31.6 million


Hepion Pharmaceuticals, Inc. (HEPA) - Business Model: Revenue Streams

Potential Licensing Agreements

As of Q4 2023, Hepion Pharmaceuticals has not reported any active licensing agreements for its lead drug candidate CRV431.

Future Drug Commercialization

Drug Candidate Therapeutic Area Current Development Stage Potential Market Value
CRV431 Non-Alcoholic Steatohepatitis (NASH) Phase 2 Clinical Trials $35 billion potential market by 2026

Research Grants and Funding

For fiscal year 2023, Hepion Pharmaceuticals reported $3.2 million in research and development grant funding.

Strategic Pharmaceutical Partnerships

  • No active strategic pharmaceutical partnerships reported in 2023
  • Ongoing discussions with potential research collaborators

Potential Milestone Payments

Milestone Type Potential Payment Range Probability
Preclinical Development $1-3 million Medium
Clinical Trial Initiation $5-10 million Medium-High

Total revenue for Hepion Pharmaceuticals in 2023: $4.7 million


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.